A 5-year follow-up of patients in the ongoing SOLO1 trial showed that patients with advanced BRCA-mutated ovarian cancer who had finished platinum-based chemotherapy had a significantly longer median progression-free survival when they received 2 years of olaparib as a maintenance therapy instead of placebo—56 months versus 13.8 months, respectively.

中文翻译：

---

作为维持治疗，奥拉帕尼的益处继续存在

正在进行的 SOLO1 试验中对患者的 5 年随访显示，完成铂类化疗的晚期 BRCA 突变卵巢癌患者在接受 2 年奥拉帕尼作为维持治疗时，中位无进展生存期显着延长治疗而不是安慰剂——分别为 56 个月和 13.8 个月。